Related Experiment Videos
Bone marrow purging with mafosfamide--a critical survey
H Sindermann1, M Peukert, P Hilgard
1ASTA-Pharma AG, Department of Clinical Cancer Research, Frankfurt, Federal Republic of Germany.
Blut
|November 1, 1989
Summary
Autologous bone marrow transplantation (ABMT) uses purging to remove tumor cells. Mafosfamide purging may improve remission duration in acute leukemia patients compared to nonpurged ABMT.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Autologous bone marrow transplantation (ABMT) is a key consolidation therapy for hematological malignancies.
- Reimplantation of residual tumor cells during ABMT poses a significant risk.
- Effective purging strategies are crucial to enhance treatment outcomes.
Purpose of the Study:
- To review the efficacy and safety of mafosfamide for purging bone marrow in ABMT.
- To evaluate the impact of mafosfamide purging on remission duration in acute leukemia.
- To synthesize chemical, experimental, and clinical data on mafosfamide purging.
Main Methods:
- Review of chemical and experimental data on mafosfamide.
- Analysis of clinical results from studies involving mafosfamide purging.
- Comparison of outcomes between purged and nonpurged ABMT in acute leukemia.
Main Results:
- Mafosfamide is an extensively studied oxazaphosphorine derivative for pharmacological purging.
- Clinical data suggest mafosfamide purging may lead to superior remission duration in acute leukemia.
- The review emphasizes the safety aspects of mafosfamide purging.
Conclusions:
- Mafosfamide purging is a promising strategy to improve ABMT efficacy in hematological diseases.
- Further investigation into the safety and efficacy of mafosfamide is warranted.
- Optimizing purging techniques is essential for maximizing the benefits of ABMT.